Guided Therapeutics (GTHP) Receivables (2010 - 2026)

Guided Therapeutics has disclosed Receivables across 17 years of filings, most recently posting $4000.0 for Q2 2026.

• In Q2 2026, Receivables fell 50.0% year-over-year to $4000.0; the TTM figure through Jun 2026 stood at $4000.0 (down 50.0% YoY), while the FY2025 annual figure was $4000.0, up 33.33% from the prior year.
• Receivables came in at $4000.0 for Q2 2026 at Guided Therapeutics, roughly flat from $4000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $165.1 million in Q1 2022 to a low of $2000.0 in Q1 2025.
• Average Receivables over 5 years is $9.2 million, with a median of $7221.0 recorded in 2023.
• Year-over-year, Receivables surged 4609.93% in 2022 and slumped 99.97% in 2023.
• Over 5 years, Receivables stood at $130984.0 in 2022, then sank by 94.32% to $7442.0 in 2023, then plunged by 59.69% to $3000.0 in 2024, then surged by 33.33% to $4000.0 in 2025, then changed by 0.0% to $4000.0 in 2026.
• Per Business Quant data, the three most recent Receivables figures were $4000.0 in Q2 2026, $4000.0 in Q1 2026, and $4000.0 in Q4 2025.